First-in-human trial of TEAD inhibitor BPI-460372 shows early signals and safety limits
A first-in-human phase Ia trial reports that the covalent TEAD palmitoylation inhibitor BPI-460372 showed preliminary antitumor activity in advanced solid ...
Tag: cardiac adverse events
POPULAR NEWS
-
Blood sedimentation rate predicts death risk in dogs with chronic kidney disease
-
Poor Preoperative Nutrition Linked to Higher Complications and Lower Survival After Hip Replacement
-
New DARPA-funded project aims to cut AI energy use by up to half
-
Antarctic Pond Bacterium Survives Calcium Levels Once Thought Fatal to Life